Anti-parasitic immunological compositions
AssigneesSamer Al-Murrani, Board of Regents of the University of Nebraska
InventorsPaul Davis, Samer Al-Murrani
Life of this patent
Estimating the term…
Abstract
Anti-parasitic compounds and uses thereof. Compounds comprising a C-terminal peptide adjuvant conjugated to an N-terminal peptide antigen via a protease-cleavable linker, said peptide adjuvant comprising a peptide analog of C5a, wherein said peptide antigen comprises an antigenic epitope of a parasitic organism, such as T. gondii. Methods of therapeutic or prophylactic treatment of a parasitic infections.
Claims18
A method of inducing an immune response to a parasitic infection caused by Toxoplasma gondii, said method comprising administering an anti-parasitic compound to a subject in need thereof, wherein said anti-parasitic compound comprises an N-terminal peptide antigen conjugated to a C-terminal peptide adjuvant via a protease-cleavable linker, said peptide adjuvant comprising a peptide analog of C5a, wherein said peptide analog is a hydrochloride salt form of EP67 YSFKDMP(MeL)aR (SEQ ID NO:2), or a conformationally-stable analog thereof, comprising the formula:
- (SEQ ID NO:
- 1)
- Tyr-Ser-Phe-Lys-Asp-Met-Xaa-(Xaa2)-(D-Ala)-Arg,
- or HCl salt form thereof, wherein Xaa is a modified proline residue or a residue substitution for proline, and Xaa2 is leucine or N-methyl leucine;
- and wherein said peptide antigen comprises an antigenic epitope of Toxoplasma gondii.
Dependencies are inferred from the claim text.